A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Start Date
9/17/2026
Completion Date
6/18/2028
Summary
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who use a breathing machine (positive airway pressure \[PAP\] machine). People may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training. During the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Berobenatide
Placebo
Conditions
Locations
Cullman Clinical Trials
Cullman, Alabama 35055
United States
Probe Clinical Research Corporation
Riverside, California 92501
United States
DM Clinical Research
Bradenton, Florida 34209
United States
Headlands Research - Twin Cities
Maplewood, Minnesota 55109
United States
Velocity Clinical Research, Dallas
Dallas, Texas 75230
United States
DM Clinical Research
Tomball, Texas 77375
United States